Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04044768 · ClinicalTrials.gov registry record · Phase 2
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Phase 2 study of Synovial Sarcoma and Myxoid Liposarcoma, sponsored by Uswm CT.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT04044768: Active Phase 2 study of Synovial Sarcoma and Myxoid Liposarcoma, sponsored by Uswm CT.
NCT04044768 is a Phase 2 study of Synovial Sarcoma and Myxoid Liposarcoma that is active but no longer recruiting, run by Uswm CT. The registered enrollment target is 52 participants, below the 152-participant average among 11 other Synovial Sarcoma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04044768, a Phase 2 study of Synovial Sarcoma and Myxoid Liposarcoma, is active but no longer recruiting, sponsored by Uswm CT.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
Primary Outcome
Percentage of participants with confirmed tumor response (complete \[CR\] or partial \[PR\] response) to treatment as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Independent Radiologist review (Cohort 1)
Conditions Studied
Interventions
- GENETIC afamitresgene autoleucel (previously ADP-A2M4)
Study Locations (20)
California
- City of Hope - Duarte
- Stanford Cancer Center - Palo Alto
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Other
- Centre Leon Berard - Lyon
- Hospital Haut Leveque, CHU Bordeaux - Pessac
Colorado
- University of Colorado - Aurora
Illinois
- Northwestern University Robert H. Lurie Comprehensive Cancer Center - Chicago
Maryland
- National Cancer Institute - Bethesda
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2038-04-01 |
| Phase | Phase 2 |
What the registry record for NCT04044768 still lists
NCT04044768 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 152-participant average among 11 other Synovial Sarcoma trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with Synovial Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which afamitresgene autoleucel (previously ADP-A2M4) is the first listed.
NCT04044768 names 20 study sites across 16 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04044768 about?
NCT04044768 is a clinical study titled "Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma". This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
What is the current status of trial NCT04044768?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2019-08-13. Estimated completion is 2038-04-01.
What conditions does trial NCT04044768 study?
This clinical trial studies the following conditions: Synovial Sarcoma, Myxoid Liposarcoma.
What interventions are being tested in trial NCT04044768?
The interventions under investigation include: afamitresgene autoleucel (previously ADP-A2M4) (GENETIC).
Who is sponsoring clinical trial NCT04044768?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04044768 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Synovial Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04044768's enrollment target sits among peer trials
52 5th of 11 higher than 7 of 11 other Synovial Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Synovial Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bevacizumab and Radiation Therapy for Sarcomas
COMPLETED · Phase 2
-
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
RECRUITING · Phase 1
-
Synovial Sarcoma Registry / Biospecimen Repository
RECRUITING
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI